SEC Form 4 · accession 0001209191-17-018679
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Mar 3, 2017
Accepted (ET)
Mar 7, 2017 · 3:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 3, 2017 | J | 79,245 | $0.00 | A | 5,652,903 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. ("NIBRI") is a limited partner.
- F2The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG.